https://www.gov.uk/government/consultations/oliver-mcgowan-draft-code-of-practice/oliver-mcgowan-draft-code-of-practice-on-statutory-learning-disability-and-autism-training<\/a><\/p>For healthcare, we estimated that over the first three years of training roll-out, 1,036,000 staff would be trained at Tier 1 level, and 1,186,000 staff would be trained at Tier 2 level. For adult social care, over the same period, we estimated that 840,000 staff would be trained at Tier 1 level, and 492,000 staff would be trained at Tier 2 level. In addition, over 1.7 million people have already completed the first part of Oliver McGowan Mandatory Training on Learning Disability and Autism, an e-learning package.<\/p>
The final stage impact assessment incorporates additional evidence on the number of staff expected to undertake training, which was provided by organisations through the public consultation. The final assessment will be published in due course.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4492", "label" : {"_value" : "Biography information for Maria Caulfield"}
}
, "answeringMemberConstituency" : {"_value" : "Lewes"}
, "answeringMemberPrinted" : {"_value" : "Maria Caulfield"}
, "dateOfAnswer" : {"_value" : "2024-04-30", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2024-04-30T10:04:00.157Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2024-04-25", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Autism and Learning Disability: Training"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, if she will make an estimate of the number of health and adult social care staff that will undertake the second part of tier (a) one and (b) two of the Oliver McGowan Mandatory Training on Learning Disability and Autism in the next three years.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4048", "label" : {"_value" : "Biography information for Caroline Nokes"}
}
, "tablingMemberConstituency" : {"_value" : "Romsey and Southampton North"}
, "tablingMemberPrinted" : [{"_value" : "Caroline Nokes"}
], "uin" : "23732"}
, {"_about" : "http://data.parliament.uk/resources/1713908", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1713908/answer", "answerText" : {"_value" : "
No estimate has been made of expected liver cancer mortality rates by the end of 2025. The care of and treatment for patients with cancer, including liver cancer, is a priority for the Government. Early diagnosis of liver cancer is critical to improving rates of survival. NHS England\u2019s Early Diagnosis of Liver Cancer Programme is contributing to the NHS Long Term Plan\u2019s commitment to diagnose 75% of all cancers at stage one or two by 2028. This programme includes three workstreams: improving liver surveillance programmes; community liver health checks pilots; and primary care pilots. Identifying those at risk and ensuring patients are tested and referred to a surveillance programme, where necessary, will lead to improved patient outcomes.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4044", "label" : {"_value" : "Biography information for Andrew Stephenson"}
}
, "answeringMemberConstituency" : {"_value" : "Pendle"}
, "answeringMemberPrinted" : {"_value" : "Andrew Stephenson"}
, "dateOfAnswer" : {"_value" : "2024-04-30", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2024-04-30T09:55:44.56Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2024-04-25", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Liver Cancer: Mortality Rates"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, whether she has made an estimate of expected liver cancer mortality rates by the end of 2025.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/1409", "label" : {"_value" : "Biography information for Mr Gregory Campbell"}
}
, "tablingMemberConstituency" : {"_value" : "East Londonderry"}
, "tablingMemberPrinted" : [{"_value" : "Mr Gregory Campbell"}
], "uin" : "23699"}
, {"_about" : "http://data.parliament.uk/resources/1713933", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1713933/answer", "answerText" : {"_value" : "
The National Contract Value Review (NCVR) process applies to commercial clinical studies. NHS England is working in partnership with the devolved administrations, the National Institute for Health and Care Research, and other partners, to pilot the use of the NCVR process for phase I and IIa of commercial clinical trials. The ambition is to make the use of NCVR for phase I and IIa of commercial clinical trials mainstream from October 2024.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4044", "label" : {"_value" : "Biography information for Andrew Stephenson"}
}
, "answeringMemberConstituency" : {"_value" : "Pendle"}
, "answeringMemberPrinted" : {"_value" : "Andrew Stephenson"}
, "dateOfAnswer" : {"_value" : "2024-04-30", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2024-04-30T09:57:50.757Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2024-04-25", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Clinical Trials: Contracts"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, with reference to the policy paper entitled Full government response to the Lord O'Shaughnessy review into commercial clinical trials, last updated on 8 December 2023, what her Department's planned timetable is for expanding the national contract value review programme to phase 1 and 2a clinical trials.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4124", "label" : {"_value" : "Biography information for Chi Onwurah"}
}
, "tablingMemberConstituency" : {"_value" : "Newcastle upon Tyne Central"}
, "tablingMemberPrinted" : [{"_value" : "Chi Onwurah"}
], "uin" : "23740"}
, {"_about" : "http://data.parliament.uk/resources/1713936", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1713936/answer", "answerText" : {"_value" : "
The Medicines and Healthcare products Regulatory Agency (MHRA) performs the functions of my Rt hon. Friend, the Secretary of State for Health and Social Care, under United Kingdom legislation, relating to the regulation of medicines, medical devices, and blood products for transfusion. The MHRA also performs the functions of my Rt hon. Friend, the Secretary of State for Health and Social Care in relation to the standardisation and control of biological medicines including vaccines, blood products, and other substances which cannot be characterised chemically, and which require special testing measures to ensure their safety and efficacy.<\/p>
My Rt hon. Friend, the Secretary of State for Health and Social Care has ministerial responsibility for, and oversight of, the MHRA\u2019s delivery and performance. The MHRA seeks ministerial agreement for policy and legislative framework changes. Ministers are not involved in individual decisions made by the MHRA. The MHRA is held to account through regular established mechanisms including quarterly and annual accountability reviews. A framework agreement between the Department and the MHRA also sets out the governance structure within which both parties operate, with further information available at the following link:<\/p>
https://www.gov.uk/government/publications/dh-and-mhra-framework-agreement/framework-agreement-between-dhsc-and-the-medicines-and-healthcare-products-regulatory-agency<\/a><\/p>The MHRA also publishes performance figures each month, as well as its annual report and accounts, and the minutes of the latest Annual Accountability Review with the MHRA is available at the following link:<\/p>
https://www.gov.uk/government/publications/annual-accountability-review-mhra/annual-accountability-review-minutes-2022-to-2023-3-july-2023<\/a><\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4044", "label" : {"_value" : "Biography information for Andrew Stephenson"}
}
, "answeringMemberConstituency" : {"_value" : "Pendle"}
, "answeringMemberPrinted" : {"_value" : "Andrew Stephenson"}
, "dateOfAnswer" : {"_value" : "2024-04-30", "_datatype" : "dateTime"}
, "groupedQuestionUIN" : {"_value" : "23761"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2024-04-30T09:52:08.65Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2024-04-25", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Medicines and Healthcare Products Regulatory Agency: Accountability"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, how the Medicines and Healthcare products Regulatory Agency is held accountable for its decisions.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4471", "label" : {"_value" : "Biography information for Rachael Maskell"}
}
, "tablingMemberConstituency" : {"_value" : "York Central"}
, "tablingMemberPrinted" : [{"_value" : "Rachael Maskell"}
], "uin" : "23760"}
], "itemsPerPage" : 10, "next" : "https://eldaddp.azurewebsites.net/answeredquestions.text?_page=1&min-dateTabled=2024-04-12&max-questionFirstAnswered.=2024-04-30T10%3A19%3A45.683Z", "page" : 0, "startIndex" : 1, "totalResults" : 2523, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]}
}